CalciMedica’s Strong Financial Position and Promising Clinical Pipeline Justify Buy Rating

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on CalciMedica (CALC – Research Report) and keeping the price target at $16.00.

Joseph Pantginis has given his Buy rating due to a combination of factors including CalciMedica’s financial stability and promising clinical developments. The company has a pro-forma cash position of approximately $28.4 million, which is expected to support operations into mid-2026, providing a solid financial runway.
Additionally, the progress in their clinical programs, particularly the ongoing Phase 2 KOURAGE trial for acute kidney injury (AKI), shows potential. The trial is on track to deliver data by the end of 2025, and previous analyses have shown significant mortality benefits for patients treated with Auxora. Furthermore, the company’s efforts in addressing acute pancreatitis and pediatric asparaginase-induced pancreatic toxicity are advancing, with plans for a Phase 3 study and ongoing Phase 2 enrollment, respectively. These developments indicate a strong pipeline that underpins the Buy rating.